IAMA THERAPEUTICS

iama-therapeutics-logo

At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families with the support they need.

#People #Website #More

IAMA THERAPEUTICS

Social Links:

Industry:
Biotechnology Life Science Pharmaceutical

Founded:
2021-01-01

Website Url:
http://www.iamatherapeutics.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
8.8 M USD



Current Advisors List

not_available_image

Laura Cancedda Founder, Scientific Advisor @ Iama Therapeutics
Advisor

not_available_image

Marco De Vivo Founder, Scientific Advisor @ Iama Therapeutics
Advisor

Current Employees Featured

andrea-patricelli-malizia_image

Andrea Patricelli Malizia
Andrea Patricelli Malizia CEO @ Iama Therapeutics
CEO

not_available_image

Annalisa Savardi
Annalisa Savardi Team Leader Neuropharmacology @ Iama Therapeutics
Team Leader Neuropharmacology

not_available_image

Marco Borgogno
Marco Borgogno Team Leader Discovery Chemistry @ Iama Therapeutics
Team Leader Discovery Chemistry

Official Site Inspections

http://www.iamatherapeutics.com Semrush global rank: 6.09 M Semrush visits lastest month: 1.33 K

  • Host name: 73.245.214.35.bc.googleusercontent.com
  • IP address: 35.214.245.73
  • Location: Mountain View United States
  • Latitude: 37.4043
  • Longitude: -122.0748
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94043

Loading ...

More informations about "Iama Therapeutics"

Iama Therapeutics - Crunchbase Company Profile & Funding

Contact Email [email protected] At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference …See details»

Iama Therapeutics Srl - Drug pipelines, Patents, Clinical trials

Www.iamatherapeutics.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. ... The statistics for …See details»

Science – IAMA Therapeutics

A signaling imbalance between excitation and inhibition in the brain causes some epilepsies and forms of autism. NKCC1 is a member of the Cation Chloride Cotransporter family, which mediate chloride transport across the membrane.. …See details»

IAMA Therapeutics - LinkedIn

IAMA Therapeutics is a clinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders.See details»

Team – IAMA Therapeutics

IAMA is a team of experienced scientists, researchers, and industry experts motivated by a shared commitment to developing new treatments to make an impact on individuals affected …See details»

IAMA Therapeutics - PitchBook

Mar 29, 2022 IAMA Therapeutics General Information Description. Developer of novel drugs intended to treat brain disorders. The company's drug can significantly alleviate the learning …See details»

IAMA Therapeutics - VentureRadar

At IAMA Therapeutics, a series-A pharmaceutical company, we are constantly pushing the boundaries of neuroscience drug discovery to develop new... ... Find out more ...See details»

Iama Therapeutics | BioPharm America

At IamaTherapeutics, a series-A pharmaceutical company, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference …See details»

IAMA Therapeutics Company Information - Funding, Investors, …

Https://iamatherapeutics.com. IAMA Therapeutics is a pharmaceutical business that develops novel therapeutics for unmet medical needs in the brain. Stay up to date with our weekly …See details»

IAMA Therapeutics Announces Approval of Clinical Trial …

GENOA, Italy, December 20, 2023--IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by …See details»

IAMA Therapeutics Announces Approval of Clinical Trial …

GENOA, Italy, December 20, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by …See details»

IAMA Therapeutics Announces Formation of Scientific Advisory …

Mar 31, 2022 IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to makeSee details»

IAMA Therapeutics - Products, Competitors, Financials, Employees ...

Cava Healthcare. Cava Healthcare is a company focused on enhancing optimal health, operating in the healthcare and biotechnology sectors. The company's main services include the …See details»

IAMA Therapeutics - BIO International Convention | BIO

Jun 7, 2023 IAMA Therapeutics is a Series A- late preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a …See details»

IAMA Therapeutics to Present at Upcoming BIO ... - Business Wire

Jun 1, 2023 GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of …See details»

IAMA Therapeutics Announces Multi-Phase, Strategic Provider …

GENOA, Italy, October 02, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by …See details»

IAMA Therapeutics Announces Multi-Phase, Strategic ... - Business …

Oct 2, 2023 IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by bSee details»

News - IAMA Therapeutics

GENOA, Italy, January 23, 2024 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by …See details»

Marco De Vivo - IAMA Therapeutics

He is also Director of the Italian CECAM-IT-SIMUL node of the CECAM (Centre Européen de Calcul Atomique et Moléculaire) organization, which promotes advanced computational …See details»